Ameriprise
CBIO

Ameriprise’s Crescent Biopharma CBIO Stock Holding History

Ameriprise’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.45M Buy
+302,568
New +$5.91M ﹤0.01% 2487
2021
Q1 		– Sell
-163
Closed -$61K – 3858
2020
Q4 		$61K Sell
163
-78
-32% -$27.3K ﹤0.01% 3715
2020
Q3 		$74K Buy
241
+31
+15% +$11.8K ﹤0.01% 3661
2020
Q2 		$79K Buy
+210
New +$59.5K ﹤0.01% 3596
2018
Q1 		– Sell
-977
Closed -$1.64M – 3647
2017
Q4 		$1.64M Buy
977
+2
+0.2% +$2.65K ﹤0.01% 2756
2017
Q3 		$1.36M Buy
975
+12
+1% +$14.1K ﹤0.01% 2818
2017
Q2 		$1.07M Buy
+963
New +$796K ﹤0.01% 2914

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ameriprise's CBIO Position: Q2 2026 in Review

Ameriprise opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 302,568 shares worth $5.45M. The stake represents ﹤0.01% of the portfolio and ranks #2487 among its holdings. This is a return to the name: Ameriprise previously reported a position in CBIO as recently as Q4 2020.

Ameriprise first reported a position in CBIO in Q2 2017 and has held it in 7 quarters since. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Ameriprise held 302,568 shares of Crescent Biopharma worth $5.45M as of Q2 2026.
  • Crescent Biopharma was a new Ameriprise position in Q2 2026.
  • Crescent Biopharma made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2487 holding.
  • Ameriprise first reported a position in Crescent Biopharma in Q2 2017 and has held it in 7 quarters since.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.